PainReform Ltd. (PRFX)

Market Cap	1.21M
Revenue (ttm)	n/a
Net Income (ttm)	-12.54M
Shares Out	2.47M
EPS (ttm)	-7.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,173
Open	0.488
Previous Close	0.496
Day's Range	0.487 - 0.517
52-Week Range	0.447 - 26.410
Beta	0.66
Analysts	Strong Buy
Price Target	2.00 (+300.8%)
Earnings Date	Aug 8, 2024

About PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 1, 2020
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: PRFX

Analyst Forecast

According to one analyst, the rating for PRFX stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target

$2.0

(300.80% upside)

Analyst Consensus: Strong Buy